Screening for AL Amyloidosis in Smoldering Multiple Myeloma | MicrobiomeTrials← Back to trialsNCT06365060
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
RecruitingOBSERVATIONAL
Trial Details
Start: 2024-05-01Est. Completion: 2029-02-27
Enrollment target: 400 participants Locations- University of Alabama Hospital, Birmingham, Alabama, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- University of California, San Francisco, San Francisco, California, United States
- Cleveland Clinic Florida, Weston Hospital, Weston, Florida, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- Columbia University Irving Medical Center, New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
- UNC Lineberger Comprehensive Cancer Center, Durham, North Carolina, United States
- The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- UT Southwestern, Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States
- University of Utah, Huntsman Cancer Hospital, Salt Lake City, Utah, United States
- VCU Medical Center, Richmond, Virginia, United States
Other microbiome trials you might be interested in
High Risk Smoldering Multiple Myeloma (HR-SMM)
This study is researching an experimental drug called linvoseltamab (also called "study drug") compared to another drug …
Phoenix, United StatesEst. completion Jul 27, 2033
Smouldering Myeloma
The study will test a new combination of 3 drugs: Isatuximab (Isa), Iberdomide (Iber) and Dexamethasone (Dex), in patien…
Leeds, United KingdomEst. completion Nov 1, 2032